Bioliberty is a technology company.
Bioliberty has raised $3.0M across 1 funding round.
Bioliberty has raised $3.0M in total across 1 funding round.
Bioliberty has raised $3.0M in total across 1 funding round.
Bioliberty's investors include Archangel Investors.
Bioliberty is a medtech startup founded in 2020 that develops soft robotic wearables, including the Lifeglov exoskeleton glove and Lifehub digital therapy platform, to assist hand rehabilitation for patients with mobility-limiting conditions like stroke, trauma, MS, or arthritis.[1][2][3][5] These products target individuals with hand weakness—over 2.5 million in the UK alone—affecting daily tasks such as driving, cooking, or dressing, enabling at-home or clinical use to restore independence through gamified therapy, AI insights, and progress tracking.[1][3][5] The company serves clinicians, rehabilitation clinics, and patients, solving therapy access issues amid rising healthcare costs and staffing shortages by scaling personalized recovery.[1][5] Bioliberty has raised $3.45M total, including a recent £435K (~$570K) grant, achieved FDA registration for Lifeglov and Lifehub, and partnered with Mount Sinai and US providers, showing strong growth momentum toward US market entry.[1][2][3]
Bioliberty emerged in 2020 from a personal crisis: co-founder Rowan witnessed a family member's loss of independence due to a neurological condition, inspiring the question, "What if we could give that independence back?"[1] Founders Rowan, Ross, Shéa, and Conan—engineers with expertise in product design, innovation, and medtech—united their skills; Ross drives technical vision and product strategy, while Conan, a top Queen's University Belfast graduate who scaled Bloc Blinds into medical device maker Bloc Medical during the pandemic, leads commercial expansion with NHS and US partnerships.[1] Early milestones included a first patent grant, $3M pre-seed raise, FDA registration for Lifeglov and Lifehub, and a clinical study with Mount Sinai, building on University of Edinburgh roots and breakthroughs in machine learning, robotics, and biomedical processing.[1][2][3] A 2023 £2.2M round led by Archangels fueled Lifeglov completion and FDA pursuits.[3][4]
Bioliberty rides the explosion in rehabilitative robotics and AI-driven medtech, fueled by aging populations, stroke prevalence (affecting hand function in millions), and post-pandemic therapy bottlenecks like staffing shortages and rising costs.[1][2][5] Timing aligns with advancements in soft robotics, machine learning, and biomedical processing, enabling scalable, home-based solutions that extend clinical reach—critical as global demand for independent living grows.[3][5] Market forces favor it: UK medtech hubs like Edinburgh's ecosystem (Heriot-Watt, University of Edinburgh) provide expertise, while US FDA progress and partnerships tap a massive rehab market.[1][2][3][6] Bioliberty influences by pioneering "therapy scaling," blending hardware/software to democratize recovery, potentially expanding to degenerative conditions and inspiring AI-robotics hybrids in healthcare.[1][5]
Bioliberty is poised to disrupt hand rehab with its FDA-cleared, AI-enhanced ecosystem, leveraging recent grants for accelerated trials, US commercialization, and Lifehub Clinic rollout.[2][5] Next steps include broader clinical adoption, lower-limb expansions, and partnerships with global providers amid AI-medtech convergence and tele-rehab trends.[1][4][5] Its influence could evolve from niche stroke aid to mainstream mobility tech, empowering independence as demographics and tech mature—transforming that founding question into widespread reality.[1][3]
Bioliberty has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in April 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2023 | $3.0M Seed | Archangel Investors |